Home / Resources and Insights / Enabling Expedited Review Programs for Novel Drugs through U...
Enabling Expedited Review Programs for Novel Drugs through Upstream Supply Chain Readiness
Less than 1 min read time
Is your novel drug on its way through an expedited review program? Is every segment of your pharmaceutical supply chain...
Topics:
Is your novel drug on its way through an expedited review program? Is every segment of your pharmaceutical supply chain ready for regulatory scrutiny?
Upstream intermediates and regulatory starting materials are often neglected. Learn from industry experts Dr. Valdas Jurkauskas, VP of Technical Operations at Black Diamond Therapeutics, and Dr. Ke Chen, VP of Process Research & Development at WuXi STA as they discuss the best approaches to enabling expedited review programs through case studies on upstream supply chain readiness.
Access on-demand webinars & videos
Gated content
Please complete the form below to access this content.
Related Reading
Accelerating Novel Peptides into Clinical Trials with Integrated Partnership
Do you have peptide drug candidates in development?
Overcoming Key Challenges in PROTAC Drug Development
Pharmaceutical development of PROTAC (Proteolysis Targeting Chimeras) molecules presents significant challenges due to their complex molecular structures, leading to low...
